CBD Improved Memory and Reduced Alzheimer's Markers in Mouse Model | Research

The takeaway

Daily CBD injections for 28 days significantly improved spatial memory in Alzheimer's mice while reducing amyloid plaques, tau tangles, neuroinflammation, and oxidative stress.

Alzheimer's researchers, neuroscientists, families exploring potential therapeutic options for dementia.

Both short- and long-term memory improved

What the researchers found

In the 5xFAD Alzheimer's mouse model, CBD decreased pTau and amyloid-beta aggregation, reduced their transport between brain regions, shifted microglia toward a neuroprotective M2 phenotype, reduced inflammatory cytokine release, and partially reversed neurite formation loss. Daily CBD injections (10 mg/kg for 28 days) significantly improved both short- and long-term spatial memory. CBD also reduced reactive oxygen species and increased neuronal survival.

Why it matters

Most Alzheimer's drugs target a single disease mechanism, but CBD addressed multiple pathological processes simultaneously: amyloid plaques, tau tangles, neuroinflammation, oxidative stress, and neuronal damage. This multi-target approach is increasingly recognized as necessary for complex neurodegenerative diseases.

The numbers in context

CBD dose: 10 mg/kg daily for 28 days. Significant improvement in short- and long-term spatial memory. Decreased pTau and amyloid-beta aggregation. Reduced ROS formation. Increased neuronal viability. Shifted microglia to M2 neuroprotective phenotype.

How the study worked

Combined in vitro and in vivo study using the 5xFAD Alzheimer's mouse model. In vitro: assessed CBD effects on protein aggregation, axonal transport, microglial polarization, neurite formation, and oxidative stress. In vivo: daily CBD injections (10 mg/kg) for 28 days with subsequent spatial memory testing.

What this study cannot tell us

Mouse model (5xFAD) does not fully replicate human Alzheimer's disease. CBD was injected, not given orally. Single dose level tested. 28-day treatment period is short relative to the chronic nature of Alzheimer's. Cannot predict human pharmacokinetics or required doses.

How to read the evidence

Preliminary: comprehensive animal study with multi-target benefits, but not yet tested in humans.

When this study was published

2025 study

The bigger picture

The failure rate for Alzheimer's drugs has been extremely high, partly because the disease involves multiple interacting pathological processes. CBD's ability to simultaneously target several of these processes in an animal model makes it an interesting candidate, though the gap between mouse models and human Alzheimer's disease remains substantial.

Questions still open

Would oral CBD at achievable human doses produce similar effects? Could CBD slow progression in early-stage human Alzheimer's? What is the minimum effective dose and treatment duration? Would CBD interact with existing Alzheimer's medications?

Common questions

Could CBD help with Alzheimer's disease?

In mice, CBD simultaneously addressed multiple Alzheimer's mechanisms and improved memory. However, many treatments that work in Alzheimer's mice have failed in human trials, so clinical studies are needed.

How did CBD work against Alzheimer's in this study?

CBD reduced both amyloid plaques and tau tangles, calmed brain inflammation by shifting immune cells to a protective state, reduced oxidative damage, and promoted neuronal survival, addressing multiple disease processes at once.

Read the original research

Cannabidiol as a multifaceted therapeutic agent: mitigating Alzheimer's disease pathology and enhancing cognitive function.

Alzheimer's research & therapy, 17(1), 109

View on PubMed ↗Publisher’s paper ↗

Citation

Raïch, Iu; Lillo, Jaume; Rebassa, Joan Biel; Griñán-Ferré, Christian; Bellver-Sanchis, Aina; Reyes-Resina, Irene; Franco, Rafael; Pallàs, Mercè; Navarro, Gemma. (2025). Cannabidiol as a multifaceted therapeutic agent: mitigating Alzheimer's disease pathology and enhancing cognitive function.. Alzheimer's research & therapy, 17(1), 109. https://doi.org/10.1186/s13195-025-01756-0